Papers
7
Total Citations
129
H-Index
6
About
Markus Aly is a leading urologic oncology researcher whose work centers on improving surgical outcomes for prostate and bladder cancer patients. His major contributions lie in understanding the prognostic significance of positive surgical margins (PSMs) after robotic radical prostatectomy, with his landmark 2023 study (48 citations) demonstrating that PSMs are independently associated with increased cancer-specific and overall mortality over a 20-year follow-up. He has also pioneered research into preoperative MRI staging to predict PSM risk (43 citations), helping surgeons refine patient selection and operative planning. Beyond prostate cancer, Aly investigates postoperative rehabilitation, leading the CanMoRe trial (10 citations) and a subsequent randomized controlled trial (8 citations) showing that structured exercise interventions after robotic cystectomy reduce complications and improve recovery. His work on 90-day cause-specific mortality after prostatectomy (8 citations) has informed national quality metrics in Sweden, where he leverages the National Prostate Cancer Register. Notably, Aly is currently investigating focal therapy through the PRIS trial (6 citations), comparing irreversible electroporation to radical treatment for localized prostate cancer. With over 120 total citations and leadership roles in the EAU Robotic Urology Section, Aly’s research directly shapes evidence-based surgical practice and postoperative care pathways.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7